Origimm Biotechnology

Origimm Biotechnology is a private Austrian biotechnology company that specializes in the development of vaccines for the treatment of diseases caused by bacteria affecting the skin.

History

2021: Sanofi bought Origimm Biotechnology

At the end of November 2021, the French medical company Sanofi acquired Origimm Biotechnology. The financial component of the transaction is not disclosed.

The acquisition of Origimm Biotechnology further expands our research and development of vaccines, with the prospect of providing the first acne vaccine, an acute medical problem for millions of adolescents and adults, "said Thomas Triumph, Executive Vice President and Global Head of Sanofi Pasteur.

Sanofi bought Austrian acne vaccine developer Origimm Biotechnology

ORI-001 is a therapeutic vaccine candidate from Origimm Biotechnology for the treatment of vulgar acne based on recombinant proteins, preliminary clinical studies of which began in the third quarter of 2021.

In September, Sanofi abandoned its plans to create its own COVID-19 mRNA-based vaccine because of the market dominance achieved - and in BioNTechPfizer Moderna using this technology to fight the virus.

Instead, the group will focus on working with the UK company GlaxoSmithKline to market another COVID-19 vaccine based on a more traditional protein-based approach.

We look forward to bringing together our expertise and strengths to continue developing innovative solutions to prevent and treat skin microbiome-related diseases such as common acne, "noted Sanya Selak, PhD, founder and CEO of Origimm Biotechnology. - Together with a strong partner like Sanofi, we will seek a paradigm shift in the treatment of skin diseases and many other microbiome-related disorders and infections for which current medical solutions are not appropriate.[1]

Notes